Virtual Cancer Cachexia Conference 2020
September 10-11, 2020

Virtual Program  

All presentations will be recorded

All Times Correspond to US EAST COAST TIME ZONE

Thursday, September 10, 2020

10:45 am Introductions – Denis Guttridge, PhD
Medical University of South Carolina, USA
Keynote Address
Denis Guttridge, PhD – Medical University of South Carolina, USA
Teresa Zimmers, PhD – Indiana University, USA
11:00 am Kenneth C.H. Fearon Keynote Lectureship
Annemie Schols, PhD
Maastricht University, Netherlands
Optimizing tumor treatment by new insights in cancer cachexia. No time to waste
12:00 pm Break
Panel Discussion: Where are we in designing the proper trial?
12:15 pm Moderators:
Marie Fallon, MD – University of Edinburgh, UK
Barry Laird, PhD – University of Edinburgh, UK

Thomas Jagoe, MD – McGill University, Canada
Tora Solheim, MD – St. Olavs Hospital, Norway
David Currow, MD – University of Technology, Australia
1:00 pm Break
Clinical Advances in Assessments and Management in Cancer Cachexia
Richard Skipworth, MD – University of Edinburgh, UK
Simon Wing, MD – McGill University, Canada
1:15 pm Richard Dunne, MD
University of Rochester, USA
Measurement selection in cachexia clinical trials: Are we missing the mark?
1:45 pm Jose Garcia, MD, PhD
University of Washington, USA
Novel insights on body composition and physical function in patients with cancer cachexia
2:15 pm Eric Roeland, MD
Harvard University, USA
The skinny on the inaugural ASCO cachexia guidelines

Back to top ...

Friday, September 11, 2020

Mechanisms of Skeletal Muscle/Organ Wasting
Andrew Judge, PhD – University of Florida, USA
Paola Costelli, PhD – University of Torino, Italy
10:00 am Imed Gallouzi, PhD
McGill University, Canada
The iNOS/NO pathway drives mitochondrial dysfunction to promote cancer-induced muscle wasting
10:30 am Norbert Perrimon, PhD
Harvard Medical School, USA
Insights on cachexia from a Drosophila model of organ wasting
11:00 am Break
11:15 am Daniel Marks, MD, PhD
Oregon Health & Science University, USA
Bystander brain injury in cancer cachexia
11:45 am Danna Breen, PhD
Pfizer, USA
Growth differentiation factor 15 (GDF-15) is a key regulator of cancer cachexia
12:15 pm Break
Next Generation Researchers in Cancer Cachexia
Rishi Jain, MD – Fox Chase Cancer Center, USA
Cynthia Stretch, PhD – University of Calgary, Canada
12:30 pm Andrew D’Lugos, PhD – University of Florida, USA
The role of complement in pancreatic cancer cachexia
12:45 pm Erin Talbert, PhD – University of Iowa, USA
Plasma ceramides as a sexually dimorphic biomarker of pancreatic cancer-induced cachexia
1:00 pm Brian Hain, PhD – The Pennsylvania State University College of Medicine, USA
Loss of REDD1 prevents chemotherapy-induced muscle atrophy and weakness in mice
1:15 pm Estefanía Simoes Fernández – University of São Paulo, Brazil
Neuronal morphology and neuroglia compromised in cancer cachexia: a post-mortem neuropathological study
1:30 pm Joshua Huot, PhD – Indiana University School of Medicine, USA
ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia
1:45 pm Brandon VanderVeen, PhD – University of South Carolina, School of Medicine, USA
The effects of chemotherapy on skeletal muscle immune cell infiltration and activation
2:00 pm Break
Cancer Cachexia Biomarker Initiative and Advancing Therapeutics
Michael Espey, PhD – National Institutes of Health, USA
Helen Heymann, PhD – Foundation of National Institutes of Health, USA
2:15 pm Tania Kamphaus, PhD
Foundation of National Institutes of Heath, USA
Introduction to FNIH and biomarker initiative
2:30 pm Teresa A. Zimmers, PhD
Indiana University, USA
Markers of cachexia in oncology – Project overview
Cancer Cachexia Society and Future Conferences
Marilia Seelaender, PhD – University of Sao Paulo, Brazil
James Carson, PhD – University of Tennessee Health Science Center, USA
3:00 pm Denis Guttridge, PhD
Medical University of South Carolina, USA
3:30 pm Closing Remarks

Back to top ...